Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
2.360
+0.020 (0.85%)
At close: Aug 25, 2025, 4:00 PM
2.330
-0.030 (-1.27%)
After-hours: Aug 25, 2025, 4:10 PM EDT
Gossamer Bio Stock Forecast
Stock Price Forecast
The 4 analysts that cover Gossamer Bio stock have a consensus rating of "Strong Buy" and an average price target of $8.50, which forecasts a 260.17% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $11.
Price Target: $8.50 (+260.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Gossamer Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +111.86% | Aug 6, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $11 | Buy | Initiates | $11 | +366.10% | Jul 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +238.98% | May 16, 2025 |
| Wedbush | Wedbush | Buy Reiterates $4 | Buy | Reiterates | $4 | +69.49% | May 16, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +196.61% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
29.88M
from 114.70M
Decreased by -73.95%
Revenue Next Year
48.99M
from 29.88M
Increased by 63.97%
EPS This Year
-0.69
from -0.25
EPS Next Year
-0.51
from -0.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.8M | 126.4M | 236.4M | ||
| Avg | 29.9M | 49.0M | 141.6M | ||
| Low | 9.7M | n/a | 51.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -45.3% | 323.1% | 382.6% | ||
| Avg | -74.0% | 64.0% | 189.1% | ||
| Low | -91.6% | - | 4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.53 | -0.12 | 0.32 | ||
| Avg | -0.69 | -0.51 | -0.16 | ||
| Low | -0.78 | -0.79 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.